A randomized, double-blinded, Phase II study in adults with Rheumatoid Arthritis receiving
TNF-alpha-inhibitor therapy aged 18 to 64 years of age and healthy gender-and age-matched
control subjects . This study will investigate the immunogenicity, safety, and reactogenicity
of two different doses of inactivated trivalent influenza virus vaccine (Sanofi Pasteur
Fluzone [15 mcg x 3 strains] and Sanofi Pasteur Fluzone High Dose [60 mcg x 3 strains])
administered intramuscularly in individuals with rheumatoid arthritis receiving
anti-TNF-alpha (TNFi) therapy and healthy age- and gender- matched controls.